Another study presented, "Predicting Cardiovascular Risk Using Common Utilization Management Criteria for Proprotein
Convertase Subtilisin/Kexin Type 9 Inhibitors in Commercially Insured Patients With Atherosclerotic Cardiovascular Disease," showed commercial payer utilization management criteria fail to prioritize patients at the highest risk for CV events.
The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial was the pivotal efficacy and safety study for the proprotein
convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab (Repatha) and enrolled patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of at least 70 mg/dL (N Engl J Med.
2-4) The most common mutations observed are in the genes for low-density lipoprotein receptor, apolipoprotein B, and proprotein
convertase subtilisin/kexin type 9 (PCSK9).
A respected cardiologist and associate professor of medicine at Harvard Medical School, Giugliano's keynote presentation will address the present and future of proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel cholesterol lowering agent and major breakthrough in cardiovascular therapeutics.
convertase subtilisin-kexin type 9 (PCSK9) inhibitors are novel drugs used to control low-density lipoprotein (LDL) cholesterol (the bad cholesterol), potentially reducing it by 5060%.
Mutations and polymorphisms in the proprotein
convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
The scientists identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell, (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing three (PNPLA3) and proprotein
convertase subtilisin/kexin type nine (PCSK9), all of which are potential targets for drug development.
FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) was eagerly anticipated as the first dedicated cardiovascular outcomes trial to report results for a proprotein
convertase subtilisin/kexin type 9 inhibitor, the novel drug class that achieves previously unattainable LDL lowering.
HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein
convertase subtilisin kexin 9 (PCSK9): an apparent "PCSK9-lipid paradox.
Within the field of lipid metabolism, the rapid clinical development of proprotein
convertase subtilisin kexin type 9 (PCSK9) inhibitors to reduce LDL cholesterol provides proof-of-concept for the potential of this approach.
The large coronary intravascular imaging trial is designed to test whether treatment with the proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha modifies atherosclerotic plaque build-up in the coronary arteries of patients already treated with optimized statin therapy.
The New Face of Hyperlipidemia Management: Proprotein
Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role as an Alternative to Statin Therapy.